Pipeline

Focused on the Future

Our robust pipeline is strategically diversified across several therapeutic areas in ophthalmology that represent attractive market opportunities and continued growth potential. Our product candidates are engineered to address specific therapeutic needs across ocular surface, anterior segment and posterior segment diseases, including the leading causes of blindness. With an aging population, there is a clear growing need for these types of innovative ocular therapies that may enhance the overall patient and physician experience.

Program Therapeutic Focus Preclinical Early/Mid Clinical Stage (Phase 1 – Phase 2) Pivotal Clinical Trial Stage (Phase 3) FDA Approval Current Status / Anticipated Milestones
Program

(axitinib intravitreal implant)

Therapeautic Process
Wet AMD*
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Pivotal Clinical Trial Stage (Phase 3)
Next Milestones
Q1 2024 Screened first subject in SOL-1 trial
Program

AXPAXLI
(axitinib intravitreal implant)

Therapeautic Process
Diabetic Retinopathy
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Next Milestones
Q2 2024 9-month data from the HELIOS Phase 1 trial
Program

(travoprost intracameral implant)

Therapeautic Process
Glaucoma and ocular hypertension
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Next Milestones
Q2 2024 Top-line data from Phase 2 trial at ASCRS in April 2024
Program

(dexamethasone intracanalicular insert)

Therapeautic Process
Episodic dry eye disease
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Next Milestones
Phase 2 trial completed
H1 2024 Complete enrollment for trial to determine placebo comparator for the potential pivotal program
Program

(cyclosporine intracanalicular insert)

Therapeautic Process
Dry eye disease
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Next Milestones
Phase 2 trial completed
H1 2024 Complete enrollment for trial to determine placebo comparator for the potential pivotal program

Program

Therapeautic Process
Post surgical ocular inflammation and pain
Ocular itching associated with allergic conjunctivitis
Preclinical
Early/Mid Clinical Stage (Phase 1 – Phase 2)
Pivotal Clinical Trial Stage (Phase 3)
FDA Approval
Next Milestones
Nearly 400,000 eyes treated to date
2023 Achieved $57.9M in net product revenue

* Age-related Macular Degeneration (AMD)

†AXPAXLI™ (axitinib intravitreal implant), also referenced as laboratory code OTX-TKI

‡PAXTRAVA™ (travoprost intracameral implant), also referenced as laboratory code OTX-TIC

Caution: All investigational product candidates are currently undergoing clinical evaluation. This chart is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval.

Learn more about our FDA-approved products